Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Annexon (ANNX) stock was in focus after the company updated investors on its late stage pipeline, highlighting a dual primary endpoint for the Phase 3 ARCHER II trial and new Guillain Barré syndrome data.
See our latest analysis for Annexon.
Against this backdrop of clinical updates and financing activity, Annexon's share price has eased in the near term, with a 30 day share price return of 5.33% and a 90 day share price return of 0.74%. In contrast, the year to date share price return of 13.65% and 1 year total shareholder return of 105% indicate that longer term momentum has been stronger than recent trading suggests.
If Annexon's recent pipeline news has caught your eye, this can be a good moment to scan the wider healthcare opportunity set using our screener for 43 healthcare AI stocks
Annexon's recent pullback comes after a strong 1 year run and fresh pipeline updates that keep expectations high. Does it make more sense to step in at today's price or wait for a clearer valuation reset?
Preferred Price to Book Ratio of 4.3x: Is it justified?
On current data, Annexon trades on a P/B of 4.3x, while the SWS DCF model suggests a future cash flow value of $104.10 per share against a last close of $5.33. That gap points to very different views between a balance sheet based snapshot and a cash flow based estimate.
The price to book ratio compares Annexon's market value to its net assets. For early stage biopharma companies with limited revenue and ongoing losses, P/B can be a blunt tool because much of the perceived value sits in clinical programs that are not fully reflected in book value.
Annexon's P/B of 4.3x stands above both the US biotechs industry average of 2.4x and the peer average of 3.3x. That signals investors are paying a richer multiple of book value than for many comparable companies, even though Annexon is unprofitable and reports net income of a $198.33 million loss with less than $1 million in revenue. Against that backdrop, the SWS DCF model, which projects future cash flows and discounts them back to today, implies a very large gap between the current share price and its estimate of intrinsic value at $104.10. This contrast highlights how sensitive valuation can be to assumptions about future earnings, clinical success outcomes, and eventual commercialization.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price to book ratio of 4.3x (OVERVALUED)
However, Annexon's story could change quickly if key late stage trials disappoint or if continued losses of $198.333 million strain its US$874.9m market cap.
Find out about the key risks to this Annexon narrative.
Another View on Annexon's Valuation
The P/B of 4.3x paints Annexon as expensive relative to peers, yet the SWS DCF model points the other way. On this view, the stock trades at $5.33 compared with an estimated future cash flow value of $104.10 per share, which screens as heavily undervalued. Could both views be missing something important?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Annexon for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this mix of optimism and caution around Annexon feels familiar, use it as a prompt to act now and form your own view based on the 2 key rewards and 2 important warning signs
Looking for more ideas beyond Annexon?
Once you have a view on Annexon, do not stop there. Broader context from other opportunities can sharpen your judgement and help you spot what others might overlook.
-
Target potential turnarounds by reviewing 19 elite penny stocks with strong financials that combine smaller market caps with stronger underlying financial profiles than many expect.
-
Strengthen your watchlist with 85 resilient stocks with low risk scores that score well on resilience, so short term volatility is less likely to derail your long term plan.
-
Get ahead of the crowd by scanning the screener containing 20 high quality undiscovered gems that pair solid fundamentals with relatively low attention from the wider market.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ANNX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
